(Reuters) – Altimmune Inc said on Tuesday that its obesity drug helped reduce weight by 10.7% on average in a mid-stage trial, but concerns over the safety of the drug sent the company’s shares falling 40% in premarket trading.
Nausea and vomiting were the most common adverse events and one patient experienced a serious case of nausea and vomiting, requiring rehydration, the company said.
(Reporting by Sriparna Roy in Bengaluru; Editing by Savio D’Souza)
